Clinical Trial

Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

Study acronym: ESTROTIMP

Active, Not Recruiting Phase 4

Summary

This is a multi-center study in France to evaluate the impact of ESTROTEP PET/CT results on the therapeutic management of patients with metastatic breast cancer (MBC). Each patient will be screened to determine whether the patient meets all the inclusion criteria and none of the exclusion criteria. After inclusion, a standardized pre ESTROTEP PET/CT questionnaire will be completed by the investigators to evaluate the initial management plan. Patient will perform the ESTROTEP PET/CT examination at visit 2. A standardized post ESTROTEP PET/CT questionnaire will then be completed by the investigators. Patients will be followed for 12 months to evaluate their clinical status and standard of care investigations.

Protocol Amendment History 4 amendments

This ClinicalTrials.gov record has been amended 4 times since 2022-08-02; most recent amendment 2025-08-11.

Status change: Recruiting → Active, Not Recruiting 2025-02-10

Trial Details

NCT Number	NCT05486182
Lead Sponsor	GE Healthcare Collaborators: Simbec-Orion Group, Keosys
Conditions	Metastatic Breast Cancer
Enrollment	153 participants
Start Date	2022-02-08
Primary Completion	2025-04-18 (estimated)
Study Completion	2026-01 (estimated)
Updated on ClinicalTrials.gov	2025-08-14